17 results about "Lytic peptide" patented technology

There is provided a method of diagnosis comprising providing a sample previously isolated from a subject and analysing the sample for presence of a peptide comprising the amino acid sequence N- terminal-KSSTG (SEQ ID NO 1). The diagnosis may be for example diagnosis of a disease is selected from: osteoarthritis, early stage osteoarthritis, moderate osteoarthritis, osteoarthritis associated with risk for chip fractures of the joint or risk for avulsion fractures, severe osteoarthritis, microfractures of the joints, avulsion fractures and chip fractures of the joint.

The present disclosure provides a composition for modifying the surface of mitochondria, comprising: a polymer backbone; a first chemical moiety conjugated to the polymer backbone, the chemical moiety comprising a peptide; and a second chemical moiety conjugated to the polymer backbone, the second chemical moiety comprising triphenylphosphine. The disclosure also provides a hydrogel comprising a plurality of hydrogel particles, each particle comprising a first polymer crosslinked with an enzyme cleavable peptide to form a crosslinked polymer and at least one mitochondria, wherein each hydrogel particle has an average diameter no greater than 100 microns. Methods of treating a disease and / or injury in a subject by administering the hydrogel are also provided.

To provide protease-responsive drug delivery hydrogels, uses thereof, and related methods of their production, more particularly, to provide hydrogels which release anti-inflammatory agents upon reaction with inflammation-related proteases.SOLUTION: A drug-loaded protease-responsive hydrogel is provided, comprising: a) a drug covalently bound to a protease-cleavable peptide anchor having a functional moiety; b) a polymer building block comprising a multi-arm polyethylene glycol (PEG) polymer having at least one functional moiety; and c) a bis-functional crosslinker comprising a peptide substrate flanked by spacer sequences containing functional moieties; wherein the drug and the arm of the multi-arm PEG polymer are covalently bound through the functional moiety of the peptide anchor, and a gel is formed by covalent bonding between the functional moiety of the polymer building block and the functional moiety of the bis-functional crosslinker.SELECTED DRAWING: Figure 19

Provided herein are synthetic peptides that replicate the cell-signaling and biological activities of full-length shed prion protein (PrPc), and a synthetic 4-mer peptide (KPSK), with two Lys residues, derived from the structure of P3 peptide having sequence of QWNKPSKPKTNMKH, which have uniquely broad anti-inflammatory activity. Further disclosed are methods of treating diseases associated with innate immunity and neuroinflammation using the peptides disclosed.

A preparation method of a liposome encapsulating a polypeptide, suberoylanilide hydroxamic acid (SAHA), and vitamin A is provided, including the following steps: dissolving choline, cholesterol, an anti-angiogenic lytic peptide, the SAHA, and the vitamin A in a chloroform-methanol solution and mixing evenly, and subjecting an obtained mixed solution to spin drying under reduced pressure to form a film; and subjecting the film to hydration with a phosphate-buffered saline (PBS) solution or ddH2O to obtain the liposome. Use of the preparation method is further provided, where a liposome prepared by the preparation method is used as a drug for treating hepatic fibrosis. An “anti-hepatic fibrosis drug” is combined with “liver-targeted vitamin A” to construct a “target liposome encapsulating the anti-hepatic fibrosis drug”.

Provided herein are cleavable peptides, cleavable peptide-based linkers, and compounds or conjugates containing the same, comprising an enzyme substrate peptide adjacent to a self- immolative dipeptide. The self-immolative dipeptides described herein can be bonded to a payload (e.g., a drug) via an ester or thioester bond, enabling traceless release of the payload following enzymatic cleavage of the substrate. Also provided herein are methods and compositions for using and producing the compounds and conjugates described herein, for example, for treating cancers.

To provide conjugated virus-like particles (VLPs).SOLUTION: Provided is a conjugated virus-like particle, comprising: (a) a capsid protein that binds a cancer cell; and (b) a fusion protein comprising at least i) a cleavage peptide sequence cleaved by a protease in a tumor environment, and ii) at least one recall protein sequence, the recall protein sequence encoding a protein or fragment thereof having a sequence that is an epitope capable of being bound by an MHC class 1 molecule on a tumor cell, thereby recruiting a pre-existing T cell in a subject, and the cleavage sequence being conjugated to the capsid protein.SELECTED DRAWING: Figure 1

The present invention belongs to the technical field of monoclonal antibody preparation, and specifically relates to a method for preparing a branched polypeptide that simulates the antigenicity of CD31 linear molecules. The method comprises the following steps: step 1. experimental material preparation; step 2. experimental instrument preparation; step 3. amino acid activation; step 4. amino acid connection to resin; step 5. removal of Fmoc protecting group of amino acid; step 6. peptide resin cleavage; step 7. polypeptide separation; step 8. polypeptide separation, purification and analysis. The invention successfully prepares monoclonal antibodies using branched peptide chains instead of linear peptide chains, which has production significance. This method reduces costs, speeds up preparation, and improves antibody quality. Peptide synthesis only takes a short time. The prepared monoclonal antibodies can be used for WB and IHC experiments, meeting the needs of different antigenic determinants. In short, the monoclonal antibodies prepared by branched peptide chains have the characteristics of precise positioning, low cost, high efficiency and versatility.

Peptide linkers sensitive to cleavage by cathepsin proteases are provided in the present disclosure. Further provided are fusion proteins comprising cathepsin protease-sensitive peptide linkers. Methods of cleaving a fusion protein via contact with a cathepsin protease are further provided.

In an embodiment of the invention, a composition for treating a cell population comprises a medicant. The medicant moiety can be an illudofulvene analog. In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The affinity moiety can be an antibody, an antibody fragment, a receptor protein, a peptidic growth factor, an anti-angiogenic protein, a specific binding peptide, protease cleavable peptide, a glycopeptide, a peptide, a peptidic toxin, a protein toxin and an oligonucleotide. The affinity moiety can be covalently bound to the medicant via a linker.

The present application relates to an anticancer lipopeptide C8H 15 Preparation of O-Asp-Ser-Asp-Val-Trp-Trp-Gly-Gly-Arg-Arg-Leu-Leu-Arg-Arg-Leu-Arg-Arg-Leu and its application in antitumor treatment, belonging to the field of biological medicine. The anticancer lipopeptide is prepared based on the key biological characteristics (positive charge, alpha-helix structure and amphiphilicity) of membrane lytic peptide. The present application provides a solid-phase synthesis method of the anticancer lipopeptide. The present anticancer lipopeptide has the characteristics of small hydrophobic moment, low hemolytic activity and good serum stability, can effectively make up for the defects of most anticancer peptides with high hemolytic toxicity, and solve the problem of poor in-vivo stability of peptide drugs. In-vitro anticancer experiments and in-vivo antitumor experiments prove that the present anticancer lipopeptide has good antitumor effect and good application prospect.

Various embodiments are described herein for a device and method for detecting bacteria. Included is a needle apparatus for detecting a bacteria comprising a plurality of working electrodes, each working electrode of the plurality having a detecting face and extending from the detecting end to the connecting end and comprising: an electrically conductive surface the detecting face of each working electrode, a peptidic probe immobilized on at least a portion of the electrically conductive surface, the peptidic probe comprising an electroactive moiety and a cleavable peptide, the cleavable peptide optionally comprising at least one linker; a reference electrode; an electrode spacer configured to support and align the plurality of working electrodes and the reference electrode each inserted or insertable therein; a syringe hub counter-electrode, optionally configured to mate with and receive the electrode spacer.

Described herein are biodegradable drug delivery conjugates and anti-cancer conjugates for effectively delivering anti-cancer agents to a subject. The conjugates include a single first cleavable peptide linker covalently connected to two polymeric segments, wherein at least one PD-L1 inhibitor is covalently bonded to each polymeric segment (referred to herein as “a PD-L1 inhibitor polymer conjugate”). Also described herein is the use of the PD-L1 inhibitor polymer conjugates in combination with anticancer agents to treat or prevent cancer.

The invention belongs to the field of biological medicines, and provides a preparation method and application of a stapled peptide and micromolecular antitumor drug covalent conjugate with high stability and strong antitumor activity. Traditional micromolecular antitumor drugs such as camptothecin, chlorambucil and the like have the problems of low water solubility, low bioavailability, poor stability, drug resistance and the like. The camptothecin or chlorambucil is covalently coupled with the stapled peptide through AEA, so that the water solubility of the small molecule medicine is remarkably improved, the anti-tumor onset time is remarkably shortened, and the long-lasting tumor cell proliferation inhibition capability is shown. Compared with linear peptide, the stability of the stapled peptide is remarkably improved, and a polypeptide drug coupling strategy based on the stapled peptide solves the problem of poor stability of polypeptide in a coupled drug on one hand, and provides a new thought for further development of classical anti-tumor drugs on the other hand.

The present invention relates to the efficient delivery of anti-infective activity, immune modulators, or growth-promoting biomolecules directly to the gastrointestinal tract of animals via a biodelivery platform.SOLUTION: The biodelivery platform can be a genetically modified microorganism. Delivery can be achieved using Lactobacillus species fix in the gastrointestinal tract. The anti-infective activity can be a bactericidal or bacteriostatic peptide, an antibody or fragment thereof that specifically recognizes a pathogen, or a phage or lytic peptide derived from a phage that specifically targets a particular pathogen.SELECTED DRAWING: None

The present invention relates to efficient delivery of anti-infective activity, immunomodulatory factors, or growth-promoting biomolecules directly to the digestive tract of an animal via a live delivery platform. The live delivery platform can be a genetically modified microorganism. Delivery can be accomplished with a Lactobacillus sp which colonizes the gastrointestinal tract. The anti-infective activity can be a bacteriocidal or bacteriostatic peptide, an antibody or fragment thereof which specifically recognizes a pathogen, or a phage, or a lytic peptide from a phage which specifically targets a certain pathogen.

In an embodiment of the invention, a composition for treating a cell population comprises a medicant. The medicant moiety can be an illudofulvene analog. In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The affinity moiety can be an antibody, an antibody fragment, a receptor protein, a peptidic growth factor, an anti-angiogenic protein, a specific binding peptide, protease cleavable peptide, a glycopeptide, a peptide, a peptidic toxin, a protein toxin and an oligonucleotide. The affinity moiety can be covalently bound to the medicant via a linker.